Literature DB >> 1351196

Economic benefits of teaching patients with chronic obstructive pulmonary disease about their illness. The PASTMA Group.

L Tougaard1, T Krone, A Sorknaes, H Ellegaard.   

Abstract

By instructing patients in how to deal with their disease financial demands on health services may be reduced. 100 consecutive patients (aged 48 to 89) admitted to a general medical ward in Denmark with chronic obstructive pulmonary disease (COPD) were allocated randomly to receive either "personalized hospital practice" (PHP), which includes training in aspects of their disease, or standard hospital practice. Changes in "consumption" of health services per patient from 1 year before until 1 year after the intervention admission were evaluated in 82 (PHP group 42, controls 40) patients who completed the intervention phase. Each group contained about the same percentage of asthmatics and smokers. The increase in consumption of health services after intervention was on average Kr15,298 per patient per year less in the PHP group than in the control group (p = 0.048, Wilcoxon test). Consumption of general practitioner services was significantly increased in the control group compared with the PHP group (mean [95% Cl] Kr1346 [549 to 2143] vs -89 [-423 to 245] per patient per year; p = 0.001, Wilcoxon test). These differences could not be explained by changes in smoking habits. PHP reduces the consumption of health services by patients with COPD, probably by increasing patients' knowledge of disease and hence their ability to manage themselves.

Entities:  

Mesh:

Year:  1992        PMID: 1351196     DOI: 10.1016/0140-6736(92)91274-c

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  9 in total

1.  COPD education reduces consumption of healthcare services.

Authors:  B Søndergaard; H Rasmussen; M Rasmussen
Journal:  Pharmacoeconomics       Date:  1993-02       Impact factor: 4.981

2.  Cost effective management programme for heart failure reduces hospitalisation.

Authors:  C M Cline; B Y Israelsson; R B Willenheimer; K Broms; L R Erhardt
Journal:  Heart       Date:  1998-11       Impact factor: 5.994

Review 3.  Salmeterol. An appraisal of its quality-of-life benefits and potential pharmacoeconomic positioning in asthma.

Authors:  D H Peters; D Faulds
Journal:  Pharmacoeconomics       Date:  1995-06       Impact factor: 4.981

4.  Cost-utility analysis of a pharmacy-led self-management programme for patients with COPD.

Authors:  Maher R Khdour; Ashley M Agus; Joseph C Kidney; Bronagh M Smyth; James C McElnay; James C Elnay; Grainne E Crealey
Journal:  Int J Clin Pharm       Date:  2011-06-04

Review 5.  An economic overview of chronic obstructive pulmonary disease.

Authors:  H S Ruchlin; E J Dasbach
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

6.  Clinical pharmacy-led disease and medicine management programme for patients with COPD.

Authors:  Maher R Khdour; Joseph C Kidney; Bronagh M Smyth; James C McElnay
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

7.  Can disease management target patients most likely to generate high costs? The impact of comorbidity.

Authors:  Mary Charlson; Robert E Charlson; William Briggs; James Hollenberg
Journal:  J Gen Intern Med       Date:  2007-04       Impact factor: 5.128

Review 8.  How will telemedicine change clinical practice in chronic obstructive pulmonary disease?

Authors:  Michele Vitacca; Alessandra Montini; Laura Comini
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

Review 9.  Models of care across the continuum of exacerbations for patients with chronic obstructive pulmonary disease.

Authors:  Jean Bourbeau; Carlos Echevarria
Journal:  Chron Respir Dis       Date:  2020 Jan-Dec       Impact factor: 2.444

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.